靶向卵巢癌中的AXL信号通路。
Targeting the AXL signaling pathway in ovarian cancer.
作者信息
Huang Ruby Yun-Ju, Antony Jane, Tan Tuan Zea, Tan David Shao-Peng
机构信息
Department of Obstetrics & Gynaecology, National University Hospital of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Cancer Science Institute of Singapore, National University of Singapore, Singapore; NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
出版信息
Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.
Abstract
In a recent publication in , we showed that a Mes molecular subtype of epithelial ovarian cancer (EOC) harboring epithelial-mesenchymal transition (EMT) features has a unique signaling network downstream of the GAS6/AXL pathway. Our finding leads to a potential strategy for treating the Mes subtype of EOC by targeting AXL.
摘要
在最近发表于《 》的一篇论文中，我们表明，具有上皮-间质转化（EMT）特征的上皮性卵巢癌（EOC）的Mes分子亚型在GAS6/AXL通路下游具有独特的信号网络。我们的发现为通过靶向AXL治疗EOC的Mes亚型提供了一种潜在策略。
相似文献
1
Targeting the AXL signaling pathway in ovarian cancer.靶向卵巢癌中的AXL信号通路。
Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.
2
3
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.抑制 PI3K/Akt/mTOR 信号通路通过逆转上皮-间充质转化和降低癌症干细胞标志物表达来减轻卵巢癌的化疗耐药性。
BMC Cancer. 2019 Jun 24;19(1):618. doi: 10.1186/s12885-019-5824-9.
4
Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.AXL对非小细胞肺癌上皮-间质转化的影响。
Exp Ther Med. 2017 Jul;14(1):785-790. doi: 10.3892/etm.2017.4532. Epub 2017 Jun 1.
5
RhoA-Dependent HGF and c-Met Mediate Gas6-Induced Inhibition of Epithelial-Mesenchymal Transition, Migration, and Invasion of Lung Alveolar Epithelial Cells.RhoA 依赖性 HGF 和 c-Met 介导 Gas6 诱导的肺肺泡上皮细胞上皮-间充质转化、迁移和侵袭的抑制作用。
Biomolecules. 2019 Oct 4;9(10):565. doi: 10.3390/biom9100565.
6
LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.长链非编码 RNA HOXD-AS1 通过靶向 miR-133a-3p 并激活 Wnt/β-catenin 信号通路促进卵巢癌细胞的增殖和侵袭。
Biomed Pharmacother. 2017 Dec;96:1216-1221. doi: 10.1016/j.biopha.2017.11.096. Epub 2017 Nov 26.
7
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.赖氨酸去甲基化酶 2A 通过调节 PI3K 通路和逆转上皮-间充质转化促进卵巢癌的进展。
Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
8
AXL receptor tyrosine kinase as a therapeutic target in NSCLC.AXL受体酪氨酸激酶作为非小细胞肺癌的治疗靶点
Lung Cancer (Auckl). 2015 Apr 30;6:27-34. doi: 10.2147/LCTT.S60438. eCollection 2015.
9
TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.转化生长因子β信号通路调节卵巢癌腹水来源球体中的上皮-间质可塑性。
Endocr Relat Cancer. 2016 Mar;23(3):147-59. doi: 10.1530/ERC-15-0383. Epub 2015 Dec 8.
10
TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.TET1 通过激活 Wnt/β-catenin 信号抑制剂 DKK1 和 SFRP2 抑制卵巢癌细胞 EMT。
Gynecol Oncol. 2017 Nov;147(2):408-417. doi: 10.1016/j.ygyno.2017.08.010. Epub 2017 Aug 26.
引用本文的文献
1
Regulation of mA (N-Methyladenosine) methylation modifiers in solid cancers.固体瘤中 mA（N6-甲基腺苷）甲基化修饰物的调控。
Funct Integr Genomics. 2024 Oct 23;24(6):193. doi: 10.1007/s10142-024-01467-z.
2
Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.鸡胚尿囊膜在癌症研究中的应用。
Cells Tissues Organs. 2022;211(2):222-237. doi: 10.1159/000513039. Epub 2021 Mar 29.
3
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.糖基磷脂酰肌醇锚定的肿瘤抑制因子OPCML在癌症中的新作用。
Cancer Gene Ther. 2021 Feb;28(1-2):18-26. doi: 10.1038/s41417-020-0187-6. Epub 2020 Jun 29.
4
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.使用六种生物标志物组合对高级别卵巢浆液性癌进行临床分层
J Clin Med. 2019 Mar 8;8(3):330. doi: 10.3390/jcm8030330.
5
The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview.TAM受体在自身免疫性疾病和癌症中的双重作用：综述
Cells. 2018 Oct 12;7(10):166. doi: 10.3390/cells7100166.
6
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?AXL 的协同失活：治愈卵巢癌的（交叉）之路？
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201846492. Epub 2018 Jul 2.
7
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.抑癌基因 OPCML 通过磷酸酶 PTPRG 促进卵巢癌细胞中 AXL 的失活。
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201745670. Epub 2018 Jun 15.
本文引用的文献
1
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.GAS6-AXL信号网络是卵巢癌间充质（Mes）分子亚型特异性治疗靶点。
Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
2
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.AXL抑制可抑制DNA损伤反应并使多种癌症细胞对PARP抑制敏感。
Mol Cancer Res. 2017 Jan;15(1):45-58. doi: 10.1158/1541-7786.MCR-16-0157. Epub 2016 Sep 26.
3
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.重新思考卵巢癌II：降低高级别浆液性卵巢癌的死亡率
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
4
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.上皮-间质转化谱定量分析及其在解读癌症患者生存情况和药物反应中的作用
EMBO Mol Med. 2014 Oct;6(10):1279-93. doi: 10.15252/emmm.201404208.
5
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.功能基因组学确定了上皮性卵巢癌中具有临床相关性和生长控制途径的五个不同的分子亚型。
EMBO Mol Med. 2013 Jul;5(7):1051-66. doi: 10.1002/emmm.201201823. Epub 2013 May 13.
6
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.上皮-间充质转化基因特征可预测对 EGFR 和 PI3K 抑制剂的耐药性，并确定 Axl 作为克服 EGFR 抑制剂耐药性的治疗靶点。
Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.
7
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.铂类化疗耐药与上皮性卵巢癌中上皮间质转化有关。
Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13.
8
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.AXL 激酶的激活导致肺癌对 EGFR 靶向治疗产生耐药性。
Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.
9
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.Axl 是乳腺癌转移和患者生存的上皮-间充质转化诱导调节因子。
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28.
10
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.BRCA2 突变型卵巢癌中继发 BRCA2 突变导致 BRCA2 蛋白功能恢复
Cancer Res. 2009 Aug 15;69(16):6381-6. doi: 10.1158/0008-5472.CAN-09-1178. Epub 2009 Aug 4.
Zotero 插件